Metrics as of 10/16/2026, 03:54 AM (Berlin time), refresh in progress.
DBV Technologies Stock
DBV Technologies S.A.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- CEO
- Daniel Tassé
- Employees
- 161
- Market cap
- $216 M
- IPO
- 22/10/2014
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in…
DBV Technologies stock: price history
1D
-0.7%
1W
-7.7%
1M
-23.2%
6M
-57.6%
YTD
-52.8%
1Y
-46.8%
2Y
+106.6%
5Y
-82.9%
10Y
-95.0%
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~25% stronger price swings than usual
Ask the agents about DBV Technologies
Analyst assessment of DBV Technologies
PRICE TARGET LOW
US$40.00
CONSENSUS
US$46.33
MEDIAN
US$48.00
PRICE TARGET HIGH
US$51.00
0
STRONG BUY
10
BUY
4
HOLD
1
SELL
0
STRONG SELL
15
TOTAL · Buy
As of: 30/06/2026
DBV Technologies stock metrics
P/E
-2.26
P/B
4.76
EV/EBITDA
-0.82
RETURN ON EQUITY
-31.4%
NET MARGIN
0.0%
DEBT/EQUITY
0.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
60.8%
FLOAT SHARES
14,539,537
AVG. DAILY VOLUME (30D)
409,408
Insider transactions (SEC)
Mohideen Pharis
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about DBV Technologies stock
What does DBV Technologies do?
DBV Technologies S.A. is a company in the Healthcare sector, Biotechnology industry, headquartered in France.
The CEO is Daniel Tassé, the company employs around 161 people.
The IPO was on 22/10/2014; the stock trades on NASDAQ under the ticker DBVT.
What do analysts say about DBV Technologies stock?
15 analysts rate the stock, the consensus is Buy (as of 30/06/2026).
The average price target is US$46.33, ranging from US$40.00 to US$51.00, with a median of US$48.00.
This is an external assessment, not a statement by Market Jury.
When does DBV Technologies report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly 25% stronger than usual.
Does DBV Technologies pay a dividend?
No, DBV Technologies currently does not pay a dividend.
Which stocks are comparable to DBV Technologies?
Comparable stocks include Nanobiotix, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get DBV Technologies stock analyzed?
Clicking "Analyze stock" lets five strategies assess DBV Technologies against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.